CB1 Receptor PET Imaging Reveals Gender Differences in PTSD
Stopped early
Conditions studied: Post-traumatic Stress Disorder (PTSD)
In brief
The objective of the proposed translational study is to test a model, based upon basic science studies, exploring multisystem impairments in PTSD including endocannabinoid (eCB) and glucocorticoids in the modulation of fear memories by examining the cannabinoid type 1 (CB1) receptor in a PTSD fear circuit as well as glucocorticoid function. The investigators propose that impaired eCB signaling in PTSD resulting in the maladaptive neurobehavioral response to the stressor is associated with an upregulation of the CB1 receptors and insufficient glucocorticoid signaling.
Key facts
- Study ID
- NCT02237677
- Run by
- NYU Langone Health
- People needed
- 36
- Starts
- 2012-06-01
- Expected to finish
- 2016-03-01
- Last updated by the study team
- 2016-08-17
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- NYU School of Medicine — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.